NCT04984356CompletedPhase 1
A Phase 1 Study of of Anti-CD7 Allogeneic CAR-T Cell Therapy (WU-CART-007) in Patients With Relapsed or Refractory T-ALL/LBL
A Phase 1 Dose-Escalation and Dose-Expansion Study of Anti-CD7 Allogeneic CAR-T Cell Therapy (WU-CART-007) in Patients With Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL)/Lymphoblastic Lymphoma (LBL)
Source: ClinicalTrials.gov · Last updated 30 Sept 2025
Brief summary (registry, in English)
The purpose of this study is to evaluate the safety, recommended dose, and preliminary anti-tumor activity of WU-CART-007 in patients with relapsed or refractory (R/R) T-cell acute lymphoblastic leukemia (T-ALL) or lymphoblastic lymphoma (LBL).
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 28 (actual)
- First submitted
- 29 Jul 2021
- Start date
- 14 Jan 2022
- Primary completion date
- 8 Aug 2024
- Lead sponsor
- Allotera Therapeutics
- NCT number
- NCT04984356
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 28
- From 14 Jan 2022 to the primary completion date, 8 Aug 2024
- 12 sites in 4 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Criteria the registry did not label
- Key Eligibility Criteria:
- Diagnosed relapsed or refractory T-ALL or T-LBL, as defined by World Health Organization (WHO) classification
- Adequate renal, hepatic, respiratory, and cardiovascular function
- Life expectancy \>12 weeks
- ECOG/Karnofsky performance status 0 or 1 at screening (Adults age \>16) or Lansky Performance Status 60 and above (adolescents ≤ 16),
Age in the registry: 12 years to - · Sex: All · Does not accept healthy volunteers
Sites (12)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Peter MacCallum Cancer Centre Coordinator of this site? Confirm its status | Melbourne | Australia | Unknown status |
| Hospital Saint-Louis Coordinator of this site? Confirm its status | Paris | France | Unknown status |
| University Hospital Robert Debre Coordinator of this site? Confirm its status | Paris | France | Unknown status |
| Erasmus MC Coordinator of this site? Confirm its status | Rotterdam | Netherlands | Unknown status |
| Prinses Máxima Centrum Coordinator of this site? Confirm its status | Utrecht | Netherlands | Unknown status |
| City of Hope Coordinator of this site? Confirm its status | Duarte | United States | Unknown status |
| Children's Hospital Los Angeles Coordinator of this site? Confirm its status | Los Angeles | United States | Unknown status |
| University of Wisconsin Coordinator of this site? Confirm its status | Madison | United States | Unknown status |
| Vanderbilt University Coordinator of this site? Confirm its status | Nashville | United States | Unknown status |
| Children's Hospital of Philadelphia Coordinator of this site? Confirm its status | Philadelphia | United States | Unknown status |
| Washington University Coordinator of this site? Confirm its status | St Louis | United States | Unknown status |
| Moffitt Cancer Center Coordinator of this site? Confirm its status | Tampa | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.